



## INVEST (VIA EQUITY) IN BIOCROSS: APOE4 PROJECT

**What is the objective?** To position APOE4 as a reference biomarker for risk/prognosis of diseases related to lipid metabolism disorders (Type II Diabetes Mellitus, Atherosclerotic Cardiovascular Disease, and Alzheimer's Disease) and to identify and quantify this biomarker through Biocross tests: e4Risk and e4Quant.

**Who is the promoter?** Biocross S.L., a spin-off of the Spanish National Research Council (CSIC), with health license 7358-PS, granted by the Spanish Medicines Agency.

The company offers e4Risk (TRL8) and e4Quant (TRL7), two innovative systems for risk/prognosis of the aforementioned diseases that facilitate, through a patented method (Immunoturbidimetry), the identification of APOE4 and allow its assessment, leading to a more efficient use of healthcare resources.

**Why is it important to know the "ApoE4 Status"?** Regardless of epigenetic risk factors, and even without being affected by them, individuals (carriers of ApoE4) begin to subclinically develop these chronic diseases decades before they become evident. Clinically, they: a) Manifest at younger ages than the general population: Alzheimer's disease before age 65, atherosclerotic cardiovascular disease before age 55, and if they have developed overweight, Type II Diabetes Mellitus before age 45; b) Appear more frequently at a younger age; c) Present more aggressively than the non-carrier population. The scientific community advocates defining Apolipoprotein E4 as "a genetic modifier that accelerates chronic metabolic diseases."

**What is the importance of determining the concentration of ApoE4 in plasma?** All clinical risk/prognosis assessment scales for patients diagnosed with any of the aforementioned diseases allow determining how the disease will progress based on usual analytical and diagnostic tests.

The range of ApoE4 values will enable clinicians to make more aggressive decisions and recommendations about the need to modify epigenetic factors affecting the patient, with greater emphasis on adherence to recommended therapy.

Identifying high-risk patient groups (previously unidentified) will allow for early intervention, which will significantly influence disease progression, delay clinical onset, and result in increased healthy years of life for patients and reduced healthcare costs, shifting usual clinical practice towards personalized medicine.

### **What are the key points of the investment proposal?**

- No technological risk.
- e4Risk allows the identification of ApoE4, and e4Quant its quantification. Patients with higher plasma concentrations of this biomarker have higher risk, poorer progression, and worse response to available treatments for the mentioned diseases.
- Early diagnosis: Improves therapeutic management and healthcare administration. Diagnosis through biomarkers is well-established in clinical practice and does not require an Ethics Committee.

- Large market and high demand: Up to 20% of the population is positive for this biomarker (ApoE4). Identifying high-risk individuals improves their quality of life, facilitates follow-up, and reduces economic and social burden on Health Systems.
- Investment made: €6 million. The company has invested 6 million euros in the development of its products.
- Co-investment: In the current round (up to €1,200,000), CRB and CDTI are participating with a joint contribution of €200,000.
- Divestment and profitability: The company anticipates an exit/divestment in the next four years. The expected return, if the forecasts supporting the Business Case are met, is a 40% IRR and a multiple of 5 times the investment made.

**What are the phases of the company's market access strategy?** I: Commercialize e4Risk and e4Quant through local distributors in Spain, Portugal, and Mexico. II: Position ApoE4 as a reference biomarker for the mentioned diseases and commercialize e4Risk and e4Quant in new markets.

**Why invest in Biocross?** Because: a) It aims to position the most cost-efficient method in the market to determine the risk/prognosis of highly prevalent diseases and improve people's lives, achieving more efficient use of healthcare resources; b) High profitability can be achieved if the company's objectives are met.

**Is there additional information?** Yes, after signing an NDA, any interested investor has access to:

- Business Case and Business Plan
- e4Risk and e4Quant Dossier
- ApoE4 and Related Pathologies, particularly cardiovascular. Incidence by country.
- Ongoing Validation Trial
- Patentability Report

Abril 2024

- 
- **Disclaimer:** This information is directed exclusively to the recipient of this document, to evaluate the investment opportunity in the ApoE4 Project, and may not be distributed to third parties without the sender's prior consent.